Pharmacotherapy for Alcohol Dependence Clinical Addiction Research and Education Unit Section of General Internal Medicine Boston University Schools of.

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

Pharmacologic Treatment Options for Alcohol Dependency Damon Landreau, D.O. LCDR/USPH/USCG Flight Surgeon.
Evidence-Based Guidelines for Pharmacotherapy in Alcohol Dependence Chandan Nayak, MD Addiction Fellow University of Michigan Department of Psychiatry.
GENERALIZED ANXIETY DISORDER IN PRIMARY CARE Curley Bonds, MD Medical Director Didi Hirsch Mental Health Services Professor & Chair Charles R. Drew University.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2014.
Facts In 2008, an estimated 20.1 million Americans aged 12 or older were current (past-month) illicit drug users. (8.0% of the population) million.
Pharmacotherapy for Substance Use Disorders Vanessa de la Cruz, MD Chief of Psychiatry Mental Health and Substance Abuse Services Santa Cruz County Health.
Treatment of Psychological Disorders Overview u How can treatments be evaluated? u How do drug treatments work? u What are the different types of psychological.
Pharmacogenetics of Alcohol Use Disorders Joseph P. Schacht, Ph.D. Department of Psychiatry & Behavioral Sciences Medical University of South Carolina.
Journal Club Alcohol and Health: Current Evidence July-August 2006.
Chapter 15 Psychological Disorders. Substance Abuse and Addictions Mental illness.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2014.
Chemically Modifying Behaviors Copyright 2010:PEER.tamu.edu.
Alcohol Interventions: What the research tells us Professor Colin Drummond.
Prevalence of Alcohol Use Disorders
Copyright Alcohol Medical Scholars Program1 Alcohol: Pharmacology and Neurobiology Vijay A. Ramchandani, Ph.D. Indiana University School of Medicine.
Copyright Alcohol Medical Scholars Program1 Pathological Gambling and Alcohol Use Disorders Timothy W. Fong MD UCLA Gambling Studies Program Alcohol Medical.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
MEDICATION ASSISTED TREATMENT for OPIATE DEPENDENCY WHAT WORKS? SHELLEY ASKEW FLOYD, MS DIRECTOR OF PHARMACOTHERAPY SERVICES PYRAMID HEALTHCARE, INC.
Contemporary Treatments in the Field of Alcohol Misuse Dr Farrukh Alam Consultant Psychiatrist Director of Addictions.
Substance-Related and Impulse-Control Disorders
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
Psychological interventions in addictive disorders MRCPsych addiction psychiatry seminar March 2010.
From screening into treatment: Implementation solutions for Alcoholism therapy Thomas R. Kosten MD JH Waggoner Chair and Professor of Psychiatry & Neuroscience.
Copyright © 2007 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 17 Substance-Related Disorders – Focus on Alcoholism.
Chapter 9 Alcohol Acute effects Mechanisms of action Long-term effects
Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.
Psychopharmacology – A brief introduction. Objectives Review general categories of psychiatric disorders Review general categories of psychiatric disorders.
Treatment for Adolescents With Depression Study (TADS)
Dr. Avinash De Sousa.  State government aided hospital.  Private psychiatric set up – nursing home.  Out patient private practice.  Private general.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Raymond F. Anton, MD for The COMBINE Study Research Group
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Prepared by: Dr. Mohammad Shaikhani University of Sulaimani College of Medicine. Dept of Medicine.
 Methadone is prescribed to relieve moderate to severe pain that has not been relieved by non-narcotic pain relievers.
BACLOFEN AS AN ADJUNCT PHARMACOTHERAPY FOR THE MAINTENANCE OF ABSTINENCE IN ALCOHOL DEPENDENT PATIENTS WITH ESTABLISHED LIVER DISEASE Lynn Owens 1, Abi.
Recent Developments in the Pharmacotherapy of Alcoholism Henry R. Kranzler, M.D. Alcohol Research Center Univ. of CT School of Medicine.
Evidence Based Medicine Pharmacological Treatment of Alcohol Dependence.
Pharmacotherapy for Alcohol Dependence
Alcoholism in Finland By Simon Kaklugin and Johanna Lehtinen.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Principles of Effective Drug Addiction Treatment Health 10 The Truth About Drugs Ms. Meade.
Background and Rationale for COMBINE A Multisite Clinical Trial Sponsored by National Institute on Alcohol Abuse and Alcoholism NIH, DHHS Margaret E. Mattson,
BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions.
DRUG DEPENDENCE TOLERANCE– The need to use more and more of a drug to achieve the same effects PHYSICAL DEPENDENCE—The body needs the drug to be able to.
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
CHAPTER 12 SUBSTANCE-RELATED AND ADDICTIVE DISORDERS Copyright © 2014 McGraw-Hill Education. All rights reserved. No reproduction or distribution without.
Samantha Mohammad And Jack Utz
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
An unpleasant sensory or emotional experience associated with actual or potential tissue damage The World Health Organization (WHO) has stated that pain.
1 Varenicline for smoking cessation Robert West University College London Logroño, October
After the ED Alcohol & Drug Treatment Options Dr Mark Daglish Director of Addiction Psychiatry Royal Brisbane & Women’s Hospital.
September 2015 PHARMACOLOGY OF ADDICTIONS.  Understanding the pharmacological basis of medications used to manage dependence  Understanding how pharmacological.
Managing alcohol to support recovery in mental health Overview of the national perspective Sean Meehan Alcohol & Drugs Public Health England East Midlands.
December 10, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,
DR. FORRY J.BEN PSYCHIATRIC RESIDENT 1DR. FORRY J.BEN 2015.
The introduction of a routine offer of relapse prevention pharmacotherapy following successful alcohol withdrawal: A quality improvement project in a 20.
Drugs and Neuron Communication
Alcohol, Other Drugs, and Health: Current Evidence
Richard Saitz MD, MPH, FACP, FASAM
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Alcoholism and unhealthy use
META:PHI in Primary Care: Implementing Best Practices for Addictions
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
UNDERSTANDING DRUGS AND MEDICINCES
Pharmacologic Interventions for Unhealthy Drinking
Medications used in Treatment of Alcohol and Drug Use Disorders
Presentation transcript:

Pharmacotherapy for Alcohol Dependence Clinical Addiction Research and Education Unit Section of General Internal Medicine Boston University Schools of Medicine and Public Health Supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) R25 AA013822

Goal and Objectives Objectives To identify appropriate candidates To describe and compare efficacy To be able to prescribe pharmacotherapy and monitor for desired and adverse effects To be aware of the importance of providing or referring patients for psychosocial therapy when using pharmacotherapy To describe pharmacotherapy options for alcohol use disorders in patients with comorbid psychiatric disorders To be aware of pharmacotherapies under study but not yet ready for routine clinical use Goal: To understand the role of pharmacotherapy in the treatment of alcohol use disorders

Why Pharmacotherapy? Brain neurotransmitter physiology is abnormal Effective alcohol treatments lead to –2/3 rds reduction in alcohol problems –50% reductions in consumption at one year (with 1/3 rd abstinent or drinking moderately) But treatment is far from completely effective Even among people identified as having alcohol dependence, only 10% receive treatment Pharmacotherapy is beneficial when given in addition to nonpharmacological therapies

Psychological, medical, employment, legal, social services Removal from drinking environment Mutual (self)-help groups Counseling Motivational Disease model (12 step) Cognitive-behavioral Marital and family therapy Pharmacotherapy Disulfiram Naltrexone Acamprosate Treatment for Alcohol Dependence: Pharmacotherapy Plays a Role

Patient Selection for Pharmacotherapy All people with alcohol dependence who are: –currently drinking –experiencing craving or at risk for return to drinking or heavy drinking Considerations –Specific medication contraindications –Willingness to engage in psychosocial support/therapy –Relationship/willingness to follow-up with health provider –Outpatient or inpatient clinical setting with prescriber, access to monitoring (e.g. visits, liver enzymes)

Why is Pharmacotherapy NOT Reaching Patients? Of patients treated for alcoholism, only 3 to 13 percent receive a prescription for naltrexone Alcohol dependence treatment system is not set up for long-term prescribing Lack of awareness Evidence of modest efficacy, and lack of evidence of effectiveness in practice Side effects Lack of time for patient management Patient reluctance to take medications Medication addiction concerns Alcoholics Anonymous (AA) philosophy Price/insurance coverage

Targets of Molecular Action: Alcohol and Opioids Opioid Targets ReceptorsOpioid Receptor Alcohol Targets ReceptorsNMDA, Kainate, GABA, Cannabinoid Glycine, Nicotinic Ach, Serotonin ChannelsCalcium, Potassium TransportersDopamine, Adenosine Signaling systemsPKA, PKC, CREB, G Proteins NeuromodulatorsOpioids, CRF, Neurosteroids, NPY

Ethanol AcetateAcetaldehyde Flushing Headache Palpitations Dizziness Nausea ADH ALDH Disulfiram Fuller RK et al. JAMA 1986;256:1449

Monitored Disulfiram: Randomized studies Length of follow-up was as follows: Gerrein 1973: 8 weeks; Azrin 1976: 2 years, Azrin 1982: 6 months; Liebson 1978: 6 months. * Thirty-day abstinence at 6 months Author, YrFollow-upDisulfiramAbstinence Gerrein, %, 39% Monitored Unmonitored 40% 7% Azrin, %Monitored Unmonitored 90-98% 55% Azrin, %Monitored Unmonitored 73%* 47* Liebson, %Monitored Unmonitored 98% 79%

Prescribing Helping Patients Who Drink Too Much NIAAA, 2005 Helping Patients Who Drink Too Much NIAAA, 2005

Prescribing Disulfiram Main contraindications: recent alcohol use, pregnancy, rubber, nickel or cobalt allergy, cognitive impairment, risk of harm from disulfiram--ethanol reaction, drug interactions Main side effects: hepatitis, neuropathy Disulfiram 250 mg/d-->500 mg/d

Acamprosate Stabilizes activity in the glutamate system NMDA receptor ETHANOL glutamate CNS Neuron GABA A Receptor GABA Cl-

Acamprosate vs. Placebo 7 studies, Treatment n=1195, Control n=1027 Weighted mean difference favoring acamprosate –27 days (95% CI 18 days, 36 days), p< Proportion of patients continuously abstinent for one year –Acamprosate 23%, Placebo 15% Efficacy of Acamprosate Bouza C et al. Addiction 2004;99:811

Main contraindication: renal insufficiency Main side effect: diarrhea; pregnancy category C Prescribing Acamprosate Acamprosate 666 mg tid

The Reward Pathway The Reward Pathway Ethanol Dopamine Beta endorphin release potentiated Naltrexone prefrontal cortex nucleus accumbens VTA Firing

Efficacy of Naltrexone 14 studies Relapse to heavy drinking –Naltrexone 428/1142 (37%), Control 445/930 (48%) p< Odds Ratio (favoring naltrexone) –0.62 (95% CI 0.52,0.75) Bouza C et al. Addiction 2004;99:811

Main contraindication: opiates, pregnancy Main side effects: nausea, dizziness Prescribing Naltrexone Naltrexone 12.5 mg/d-->25 mg/d-->50 mg/d

Drugs Under Study Injectable naltrexone Topiramate Ondansetron Combinations For people with alcohol problems, but not dependence –Targeted use

Oslin DW et al. Neuropsychopharmacology. 2003;28:1546 Pharmacogenomics

Medications and Psychosocial Therapy Usually medications given along with psychosocial therapy Naltrexone & primary care management (PCM) vs. naltrexone & cognitive behavioral therapy (CBT) –Comparable results for initial 10 weeks, results favored PCM thereafter Naltrexone (vs. placebo) without obligatory therapy was was effective in treating alcohol dependence

Pharmacotherapy for Mood and Anxiety Disorders Insufficient evidence to suggest their use in patients without mood disorders SSRIs citalopram & fluvoxamine Treatment of patients with co-existing psychiatric symptoms and disorders can decrease alcohol use Anxiety: buspirone Depression: fluoxetine Nunes & Levin. JAMA 2004;291:1887 Garbutt JC et al. JAMA 1999;281:1318 Nunes & Levin. JAMA 2004;291:1887 Garbutt JC et al. JAMA 1999;281:1318

Summary Pharmacotherapy for alcohol dependence has efficacy and should be considered for all patients with alcohol dependence Pharmacotherapy has proven efficacy when prescribed along with psychosocial counseling There is no clear drug of choice for this indication Combinations of efficacious drugs and new drugs for this indication hold promise